1. Generics Bulletin
  2. >>Business
  3. >>Deals

Alvogen Strikes Deals For Pfenex’ Teriparatide

Meanwhile, Pfenex Reports Positive Results In US Equivalence Study

 
• By Aidan Fry

Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.

Dartboard
Canada and South Korea, along with Israel, are the targets of Alvogen's latest licensing deals for teriparatide • Source: Shutterstock

Alvogen has entered into exclusive commercial agreements in Canada, Israel and South Korea for the PF708 teriparatide candidate developed by its partner Pfenex. The Icelandic company has struck deals for the rival to Eli Lilly’s Forteo osteoporosis drug with JAMP Pharma in Canada, with Kamada in Israel and with Pharmbio Korea Inc. in Korea.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Coherus Marks Exit From Biosimilars By Completing Udenyca Divestment

 
• By Dave Wallace

Coherus has officially marked its exit from biosimilars by completing the divestment of its Udenyca pegfilgrastim franchise. Meanwhile, buyer Accord BioPharma has set out how it expects to benefit not only from a growing asset but also from the Coherus personnel that have moved over.

Biocon Chooses To Settle Over Eylea In US – Will Others Follow?

 
• By Dave Wallace

After Amgen’s surprise launch of the first US biosimilar to Eylea last year, expectations around competition are being further upended with the news that Biocon Biologics has struck a settlement deal with Regeneron allowing it to launch its own aflibercept rival in the second half of 2026. Will other challengers follow suit?

Emcure’s Subsidiary Tillomed Boosts Portfolio With $20m+ Manx Deal

 
• By Adam Zamecnik

The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.

Lupin Boosts UK Presence Through Renascience Acquisition

 
• By Adam Zamecnik

Lupin’s UK subsidiary acquired the British firm for an undisclosed sum of money, adding further assets into the company’s armamentarium.

More from Business

As US Launches Pharma Probe, AAM Warns Tariffs ‘Will Only Amplify Problems’

 
• By Dave Wallace

News of a fresh US investigation into the pharma sector has sparked renewed concerns over the impact that US trade tariffs would have on the generics and biosimilars industry. The AAM has responded with a warning over the potential effects on shortages and access, while Medicines for Europe has proposed five key action areas to bolster the sector in Europe.

Sandoz Attacks Amgen Over US Enbrel Exclusivity

 
• By Dave Wallace

Having failed in US patent litigation over Amgen’s Enbrel, Sandoz is taking an alternative approach in trying to get its Erelzi biosimilar to market in the US ahead of patent expiry in 2029: launching an antitrust attack against the originator for “unlawfully extending and entrenching its monopoly."

Cipla Welcomes Abraxane ANDA Approval After Tackling Goa Compliance Issues

 
• By Dean Rudge

Cipla will look to give its US operations a boost later this year by launching only the second Abraxane ANDA product.